Lol where are the $15 callers today, thats right MIA, no doubt they will be back on the next down day to remind us of where its heading.
Printable View
Lol where are the $15 callers today, thats right MIA, no doubt they will be back on the next down day to remind us of where its heading.
https://www.nzherald.co.nz/business/...ESVXZYPN3GPZE/ paywalled
Excepts. Forsyth Barr analysts downgraded Fisher & Paykel this week, dropping the stock from a neutral rating to underperform and lowering its target price from $25.05 to $20. FPH is trading well ahead of its historic strong relationship with peers, which coupled with the backdrop of negative earnings momentum, and increased earnings uncertainty, we view the risk reward as negatively skewed."
Thought for the day. $20 price target a year from now suggests with the very low dividend yield Forbar think about $18-$18.50 is fair value now.
Cant read it, I don't pay for the Herald which is mainly rubbish but no doubt some analysts opinion. Haha yeah I was right Forbars the lowest of the 10 analysts on 4 traders at $20, avg target price $27.05, you'd better do more research Beagle instead of quoting the Forbar numpties.
Its a good read that article, covers RYM, MFT, IFT, MFB and FPH. Think they're doing a special at $99 for a whole years access which seems pretty reasonable to me.
[QUOTE=couta1;956906]Cant read it, I don't pay for the Herald which is mainly rubbish but no doubt some analysts opinion. Haha yeah I was right Forbars the lowest of the 10 analysts on 4 traders at $20, avg target price $27.05, you'd better do more research Beagle instead of quoting the Forbar numpties.[/QUOTE
But others are less upbeat. Forsyth Barr analysts downgraded Fisher & Paykel this week, dropping the stock from a neutral rating to underperform and lowering its target price from $25.05 to $20."F&P Healthcare's share price has been under pressure year to date; we think there is more to come," they said.
The analysts said there was no questioning the company's quality with its strong competitive positioning, favourable long-term earnings tailwinds, high returns on
capital, and relatively low earnings volatility (pre-Covid).
"We continue to view FPH as well positioned long-term with double-digit earnings growth forecast from FY23 (our view of the new 'base') but expect the next 12 months to be
challenging.
But Jarden and Craigs are positive as they think by middle of this FY market will start looking ahead ...though all know and acknowledge that current FY is going to be lowest revenue year with making FY23 as new base year ...FY24 growth will restart and will get discounted ahead on merits
Another week …..FPH share price down again …..about a buck this week
Under 20 ….getting there